Search research articles
Contact Us
Filters
Showing results (1-10 of 120) with videos related to
Page
of 12
Sort By:
Journal of Molecular and Cellular Cardiology
|
May 28, 2011
Cardiac myosin activation part 1: from concept to clinic
Fady I Malik, Bradley P Morgan
Pflugers Archiv : European Journal of Physiology
|
May 6, 2014
Novel drug mechanisms in development for heart failure
Soidjon D Khodjaev, John R Teerlink, Fady I Malik
Journal of Cachexia, Sarcopenia and Muscle
|
September 21, 2020
Fast skeletal muscle troponin activator CK-2066260 mitigates skeletal muscle weakness independently of the underlying cause
Arthur J Cheng, Jennifer Ström, Darren T Hwee, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
March 7, 2015
A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis
Donald B Sanders, Jeffrey Rosenfeld, Mazen M Dimachkie, et al.
International Journal of Molecular Sciences
|
October 30, 2019
Functional Characterization of the Intact Diaphragm in a Nebulin-Based Nemaline Myopathy (NM) Model-Effects of the Fast Skeletal Muscle Troponin Activator <i>tirasemtiv</i>
Eun-Jeong Lee, Justin Kolb, Darren T Hwee, et al.
Nature Communications
|
August 5, 2017
Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil
Vicente J Planelles-Herrero, James J Hartman, Julien Robert-Paganin, et al.
Clinical Pharmacology in Drug Development
|
June 19, 2021
Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug-Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open-Label Studies in Healthy Subjects
Ashit Trivedi, Fady I Malik, Pegah Jafarinasabian, et al.
Journal of Clinical Pharmacology
|
May 8, 2015
Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure
Thuy Vu, Peiming Ma, Jim J Xiao, et al.
European Journal of Drug Metabolism and Pharmacokinetics
|
August 20, 2021
Pharmacokinetics, Tolerability, and Safety of Single and Multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian Subjects
Ashit Trivedi, Fady I Malik, Mia Mackowski, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 14, 2015
The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure
Darren T Hwee, Adam R Kennedy, James J Hartman, et al.
Page
of 12
Search research articles
Search
Showing results (1-10 of 120) with videos related to
Sort By:
Page
of 12
Journal of Molecular and Cellular Cardiology
|
May 28, 2011
Cardiac myosin activation part 1: from concept to clinic
Fady I Malik, Bradley P Morgan
Pflugers Archiv : European Journal of Physiology
|
May 6, 2014
Novel drug mechanisms in development for heart failure
Soidjon D Khodjaev, John R Teerlink, Fady I Malik
Journal of Cachexia, Sarcopenia and Muscle
|
September 21, 2020
Fast skeletal muscle troponin activator CK-2066260 mitigates skeletal muscle weakness independently of the underlying cause
Arthur J Cheng, Jennifer Ström, Darren T Hwee, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
March 7, 2015
A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis
Donald B Sanders, Jeffrey Rosenfeld, Mazen M Dimachkie, et al.
International Journal of Molecular Sciences
|
October 30, 2019
Functional Characterization of the Intact Diaphragm in a Nebulin-Based Nemaline Myopathy (NM) Model-Effects of the Fast Skeletal Muscle Troponin Activator <i>tirasemtiv</i>
Eun-Jeong Lee, Justin Kolb, Darren T Hwee, et al.
Nature Communications
|
August 5, 2017
Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil
Vicente J Planelles-Herrero, James J Hartman, Julien Robert-Paganin, et al.
Clinical Pharmacology in Drug Development
|
June 19, 2021
Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug-Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open-Label Studies in Healthy Subjects
Ashit Trivedi, Fady I Malik, Pegah Jafarinasabian, et al.
Journal of Clinical Pharmacology
|
May 8, 2015
Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure
Thuy Vu, Peiming Ma, Jim J Xiao, et al.
European Journal of Drug Metabolism and Pharmacokinetics
|
August 20, 2021
Pharmacokinetics, Tolerability, and Safety of Single and Multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian Subjects
Ashit Trivedi, Fady I Malik, Mia Mackowski, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 14, 2015
The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure
Darren T Hwee, Adam R Kennedy, James J Hartman, et al.
Page
of 12